Exoskeleton exercise
OtherFunctional exercise with a robotic exoskeleton
NCT Number: NCT03583879
This study evaluates the benefits of exoskeleton-based exercise for improving mood and cognition in people with Parkinson's disease (PD). Participants with PD will be assigned one of three treatments delivered over 8-weeks: exoskeleton exercise (experimental intervention), non-exoskeleton exercise (active comparator), and wait-list control (no treatment).
Looking for future studies?
Notify Me50 year–85 year
All sexes
Interventional
Not applicable
The University of New Brunswick, Fredericton, New Brunswick, Canada
Parkinson's Disease (PD) is a movement disorder that significantly impairs mobility and increases risk of falls. Many people with PD also experience mild cognitive impairment (MCI) and some progress to Parkinson's disease dementia (PDD). Non-pharmacologic treatments such as physical activity and exercise are known to be neuroprotective and may improve cognition, mood and overall functioning in PD, but such interventions can be challenging for individuals with PD and cognitive impairment to fully participate in. Robotic over-ground exoskeletons have the potential to overcome this barrier; however there are no scientific data yet to support the use robotic exoskeletons in the PD population or those with mood disorder and/or declining cognitive function.
This therapeutic exploratory trial will fill this gap in knowledge and provide critical data for understanding how to integrate exoskeletons into clinical practice for age-related movement disorders when cognitive decline is present. Specifically we will test if an 8-week functional exercise program (gait, balance, aerobic exercise) using the KEEOGO Rehab(tm) exoskeleton can improve mood and cognition, as well as gait and balance, compared to the same functional exercise without using the exoskeleton, and a wait-list control (no treatment).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Functional exercise with a robotic exoskeleton
Functional exercise without a robotic exoskeleton
Wait-list control
Time frame: Baseline and 8 weeks
10-item "Scales for Outcomes in Parkinson's-Cognition" (SCOPA-COG) instrument to evaluate cognitive function; Total score, range 0-43, higher scores = better cognitive functioning.
Time frame: Baseline and 8 weeks
14-item "Hospital Anxiety and Depression Scale" (HADS) instrument to measure mood disorder; Total score, range 0-42, higher scores = more severe mood disorder
Time frame: Baseline and 8 weeks
"Unified Parkinson's Disease Rating Scale" (UPDRS), 4-item Section I - Mentation; Sub-scale score range 0-16, higher scores = worse symptoms.
Time frame: Baseline and 8 weeks
"Unified Parkinson's Disease Rating Scale" (UPDRS), 14-item Section III - Motor; Sub-scale range 0-108, higher scores = worse symptoms.
Time frame: Baseline and 8 weeks
Brief version of Balance Evaluation Systems Test (Brief-BESTest) for balance, average of three tests.
Time frame: Baseline and 8 weeks
16 item "Activity-specific Balance Confidence" (ABC) for balance self-efficacy; Total score, 0-100, is average of items scaled on 0-100% confidence in doing specific tasks without falling, higher scores = better balance confidence
Time frame: Baseline and 8 weeks
Fast walking gait speed, average of three tests.
Time frame: Baseline and 8 weeks
Dual-task gait cost index (DTGC); Calculated index score (0-1) based on ratio of gait speed during normal gait minus gait speed with cognitive distractor divided by normal gait speed, average of three tests.
Time frame: Baseline and 8 weeks
Dual-task cognitive cost index (DTCC); Calculated index score (0-1) based on ratio of correct responses during sitting minus correct responses during gait divided by correct responses while seated, average of three tests.
Time frame: Baseline and 8 weeks
Distance covered with 6 min walking, average of three tests
Time frame: Baseline and 8 weeks
6-item "Freezing of Gait Questionnaire" (FoG-Q) for measuring the impact of freezing of gait on mobility; Total score, range 0-24, higher scores = worse symptoms.
Time frame: Baseline and 8 weeks
39-item "Parkinson's Disease health-related Quality of life" (PDQ-39) survey; Total score, 0-195, higher scores = worse health-related quality of life
Time frame: 2x per week for 8 weeks
Actigraph activity monitor for quantifying cumulative energy expenditure
University of New Brunswick
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07651085
Alzheimer Disease, Basal Ganglia Diseases
Rome, Italy
View Trial DetailsNCT03174938
ALS (Amyotrophic Lateral Sclerosis), Alzheimer Disease
Ängelholm, Sweden
View Trial DetailsNCT06529744
Alzheimer Disease, Aphasia
North York, Ontario, Canada
View Trial DetailsNCT07222605
Alzheimer Disease, Basal Ganglia Diseases
Atlanta, Georgia, United States
View Trial Details